DOSING ACCURACY OF ANTIEPILEPTIC DRUG REGIMENS AS DETERMINED BY SERUM CONCENTRATIONS IN OUTPATIENT EPILEPSY CLINIC PATIENTS

被引：4

作者：

PRIVITERA, MD

机构：

[1] UNIV TEXAS,SW MED CTR,DALLAS,TX 75230

[2] VET ADM MED CTR,CINCINNATI,OH 45220

来源：

THERAPEUTIC DRUG MONITORING | 1989年 / 11卷 / 06期

关键词：

D O I：

10.1097/00007691-198911000-00006

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页码：647 / 651

页数：5

共 30 条

[1]

ARNOLD K, 1970, CLIN PHARMACOL THER, V11, P121

[2] PHARMACOKINETICS - TIME-DEPENDENT CHANGES - AUTOINDUCTION OF CARBAMAZEPINE EPOXIDATION [J].

BERTILSSON, L ;

TOMSON, T ;

TYBRING, G .

JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (06) :459-462

[3] EFFECT OF DOSAGE INCREMENTS ON BLOOD PHENYTOIN CONCENTRATIONS [J].

BOCHNER, F ;

HOOPER, WD ;

TYRER, JH ;

EADIE, MJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1972, 35 (06) :873-876

[4] STUDIES WITH STABLE ISOTOPES .1. CHANGES IN PHENYTOIN PHARMACOKINETICS AND BIOTRANSFORMATION DURING MONOTHERAPY [J].

BROWNE, TR ;

EVANS, JE ;

SZABO, GK ;

EVANS, BA ;

GREENBLATT, DJ ;

SCHUMACHER, GE .

JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (01) :43-50

[5] STUDIES WITH STABLE ISOTOPES .2. PHENOBARBITAL PHARMACOKINETICS DURING MONOTHERAPY [J].

BROWNE, TR ;

EVANS, JE ;

SZABO, GK ;

EVANS, BA ;

GREENBLATT, DJ .

JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (01) :51-58

[6] CARBAMAZEPINE INCREASES PHENYTOIN SERUM CONCENTRATION AND REDUCES PHENYTOIN CLEARANCE [J].

BROWNE, TR ;

SZABO, GK ;

EVANS, JE ;

EVANS, BA ;

GREENBLATT, DJ .

NEUROLOGY, 1988, 38 (07) :1146-1150

[7] PHENOBARBITAL DOES NOT ALTER PHENYTOIN STEADY-STATE SERUM CONCENTRATION OR PHARMACOKINETICS [J].

BROWNE, TR ;

SZABO, GK ;

EVANS, J ;

EVANS, BA ;

GREENBLATT, DJ ;

MIKATI, MA .

NEUROLOGY, 1988, 38 (04) :639-642

[8]

GERBER N, 1972, RES COMMUN CHEM PATH, V3, P455

[9]

GODLEY PJ, 1987, CLIN PHARMACY, V6, P634

[10] PHENYTOIN CLEARANCES IN A COMPLIANT POPULATION - DESCRIPTION AND APPLICATION [J].

GRAVES, NM ;

LEPPIK, IE ;

TERMOND, E ;

TAYLOR, JW .

THERAPEUTIC DRUG MONITORING, 1986, 8 (04) :427-433

← 1 2 3 →